340 related articles for article (PubMed ID: 32887469)
1. Methods of Purification and Application Procedures of Alpha1 Antitrypsin: A Long-Lasting History.
Viglio S; Iadarola P; D'Amato M; Stolk J
Molecules; 2020 Sep; 25(17):. PubMed ID: 32887469
[TBL] [Abstract][Full Text] [Related]
2. Emphysema in alpha1-antitrypsin deficiency: does replacement therapy affect outcome?
Abboud RT; Ford GT; Chapman KR
Treat Respir Med; 2005; 4(1):1-8. PubMed ID: 15725045
[TBL] [Abstract][Full Text] [Related]
3. Alpha-1 antitrypsin augmentation therapy.
Wewers MD; Crystal RG
COPD; 2013 Mar; 10 Suppl 1():64-7. PubMed ID: 23527997
[TBL] [Abstract][Full Text] [Related]
4. Alpha1-antitrypsin deficiency: forgotten etiology.
Kaplan A; Cosentino L
Can Fam Physician; 2010 Jan; 56(1):19-24. PubMed ID: 20090075
[TBL] [Abstract][Full Text] [Related]
5. A review of α1-antitrypsin deficiency.
Stoller JK; Aboussouan LS
Am J Respir Crit Care Med; 2012 Feb; 185(3):246-59. PubMed ID: 21960536
[TBL] [Abstract][Full Text] [Related]
6. Alpha1-antitrypsin deficiency: a clinical-genetic overview.
Abboud RT; Nelson TN; Jung B; Mattman A
Appl Clin Genet; 2011; 4():55-65. PubMed ID: 23776367
[TBL] [Abstract][Full Text] [Related]
7. α
Murphy MP; McEnery T; McQuillan K; McElvaney OF; McElvaney OJ; Landers S; Coleman O; Bussayajirapong A; Hawkins P; Henry M; Meleady P; Reeves EP; McElvaney NG
Eur Respir J; 2020 Apr; 55(4):. PubMed ID: 32060059
[TBL] [Abstract][Full Text] [Related]
8. The BLT1 Inhibitory Function of α-1 Antitrypsin Augmentation Therapy Disrupts Leukotriene B4 Neutrophil Signaling.
O'Dwyer CA; O'Brien ME; Wormald MR; White MM; Banville N; Hurley K; McCarthy C; McElvaney NG; Reeves EP
J Immunol; 2015 Oct; 195(8):3628-41. PubMed ID: 26371243
[TBL] [Abstract][Full Text] [Related]
9. Introducing standards of the best medical practice for patients with inherited alpha-1-antitrypsin deficiency in Central Eastern Europe.
Valiulis A; Utkus A; Stukas R; Valiulis A; Siderius L;
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2014; 35(1):107-14. PubMed ID: 24798601
[TBL] [Abstract][Full Text] [Related]
10. Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence.
Rahaghi FF; Miravitlles M
Respir Res; 2017 May; 18(1):105. PubMed ID: 28558837
[TBL] [Abstract][Full Text] [Related]
11. Protease-Specific Biomarkers to Analyse Protease Inhibitors for Emphysema Associated with Alpha 1-Antitrypsin Deficiency. An Overview of Current Approaches.
Viglio S; Bak EG; Schouten IGM; Iadarola P; Stolk J
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33494436
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic benefits of recombinant alpha1-antitrypsin IgG1 Fc-fusion protein in experimental emphysema.
Takeda K; Kim SH; Joetham A; Petrache I; Gelfand EW
Respir Res; 2021 Jul; 22(1):207. PubMed ID: 34271910
[TBL] [Abstract][Full Text] [Related]
13. Alpha-1 Antitrypsin Augmentation Inhibits Proteolysis of Neutrophil Membrane Voltage-Gated Proton Channel-1 in Alpha-1 Deficient Individuals.
Hawkins P; Sya J; Hup NK; Murphy MP; McElvaney NG; Reeves EP
Medicina (Kaunas); 2021 Aug; 57(8):. PubMed ID: 34441020
[No Abstract] [Full Text] [Related]
14. The effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency.
Schmid ST; Koepke J; Dresel M; Hattesohl A; Frenzel E; Perez J; Lomas DA; Miranda E; Greulich T; Noeske S; Wencker M; Teschler H; Vogelmeier C; Janciauskiene S; Koczulla AR
Int J Chron Obstruct Pulmon Dis; 2012; 7():687-96. PubMed ID: 23055718
[TBL] [Abstract][Full Text] [Related]
15. Tumor necrosis factor-α driven inflammation in alpha-1 antitrypsin deficiency: a new model of pathogenesis and treatment.
Hurley K; Reeves EP; Carroll TP; McElvaney NG
Expert Rev Respir Med; 2016 Feb; 10(2):207-22. PubMed ID: 26634397
[TBL] [Abstract][Full Text] [Related]
16. Safety of Intravenous Administration of an AAV8 Vector Coding for an Oxidation-Resistant Human α1-Antitrypsin for the Treatment of α1-Antitrypsin Deficiency.
Rosenberg JB; De BP; Greco A; Gorman N; Kooner V; Chen A; Yost-Bido M; Munoz-Zuluaga C; Kaminsky SM; Rostami M; Monette S; Crystal RG; Sondhi D
Hum Gene Ther; 2023 Feb; 34(3-4):139-149. PubMed ID: 36606685
[TBL] [Abstract][Full Text] [Related]
17. Anti-inflammatory and immunomodulatory properties of α1-antitrypsin without inhibition of elastase.
Jonigk D; Al-Omari M; Maegel L; Müller M; Izykowski N; Hong J; Hong K; Kim SH; Dorsch M; Mahadeva R; Laenger F; Kreipe H; Braun A; Shahaf G; Lewis EC; Welte T; Dinarello CA; Janciauskiene S
Proc Natl Acad Sci U S A; 2013 Sep; 110(37):15007-12. PubMed ID: 23975926
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of inhaled human α-1 antitrypsin in people with α-1 antitrypsin deficiency-related emphysema.
Franciosi AN; McCarthy C; McElvaney NG
Expert Rev Respir Med; 2015 Apr; 9(2):143-51. PubMed ID: 25598013
[TBL] [Abstract][Full Text] [Related]
19. A review of augmentation therapy for alpha-1 antitrypsin deficiency.
Mohanka M; Khemasuwan D; Stoller JK
Expert Opin Biol Ther; 2012 Jun; 12(6):685-700. PubMed ID: 22500781
[TBL] [Abstract][Full Text] [Related]
20. Activation of complement component 3 is associated with airways disease and pulmonary emphysema in alpha-1 antitrypsin deficiency.
O'Brien ME; Fee L; Browne N; Carroll TP; Meleady P; Henry M; McQuillan K; Murphy MP; Logan M; McCarthy C; McElvaney OJ; Reeves EP; McElvaney NG
Thorax; 2020 Apr; 75(4):321-330. PubMed ID: 31959730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
